Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 OncoCyteVerseonLineage Cell TherapeuticsExicureMatinas BioPharma
SymbolNYSEAMERICAN:OCXLON:VSNNYSEAMERICAN:LCTXOTCMKTS:XCURNYSEAMERICAN:MTNB
Price Information
Current Price$2.73N/A$0.89$2.73$0.90
52 Week RangeBuyN/ABuyBuyBuy
Beat the Market™ Rank
Overall Score1.90.51.31.31.9
Analysis Score3.50.03.53.53.5
Community Score2.82.42.93.02.8
Dividend Score0.00.00.00.00.0
Ownership Score3.00.00.00.03.0
Earnings & Valuation Score0.00.00.00.00.0
Analyst Ratings
Consensus RecommendationBuyN/ABuyBuyBuy
Consensus Price Target$6.25N/A$3.50$7.33$3.30
% Upside from Price Target128.94% upsideN/A293.21% upside168.62% upside267.03% upside
Trade Information
Market Cap$158.05 million£127.41 million$136.31 million$228.33 million$134.45 million
BetaN/AN/AN/AN/AN/A
Average Volume283,771560926,524279,2932,357,262
Sales & Book Value
Annual RevenueN/AN/AN/AN/AN/A
Price / SalesN/AN/AN/AN/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/A6.61N/AN/AN/A
Book ValueN/AGBX 21 per shareN/AN/AN/A
Price / BookN/AN/AN/AN/AN/A
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSN/AGBX (14.30)N/AN/AN/A
Trailing P/E Ratio0.00N/A0.000.000.00
Forward P/E RatioN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A74.84%N/AN/AN/A
Current RatioN/A3.36%N/AN/AN/A
Quick RatioN/A3.09%N/AN/AN/A
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
Employees12N/A762721
Shares Outstanding67.22 million151.67 million149.82 million87.15 million197.49 million
Next Earnings Date8/12/2020 (Estimated)N/A8/13/2020 (Estimated)N/A8/11/2020 (Estimated)
OptionableNot OptionableNot OptionableOptionableNot OptionableNot Optionable

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.